Tempest Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Tempest Therapeutics
Pharmaceutical Preparations, SIC 2834
Tempest Therapeutics is a clinical-stage biotechnology company that develops targeted therapies for oncology and immunology indications. The company focuses on advancing cell therapy and small-molecule product candidates. Its primary cell therapy programs include TPST-2003, an autologous dual-targeting CAR-T therapy evaluated for relapsed or refractory multiple myeloma and POEMS syndrome, alongside additional autologous, allogeneic, and in vivo CAR-T candidates targeting conditions like solid tumors and lupus. Tempest also advances two clinical-stage small-molecule candidates, amezalpat, an oral PPARα antagonist evaluated for hepatocellular carcinoma, and TPST-1495, an oral dual antagonist of EP2 and EP4 receptors evaluated for familial adenomatous polyposis. Its therapies are designed for patients facing high unmet medical needs in oncology and related fields.
The company conducts clinical and preclinical studies across international territories, with trials underway in China and planned developments in the United States. Its asset licenses cover global territories excluding Greater China, India, Russia, and Turkey. The provided text does not state the company's headquarters or specific facility counts.
Summary of the business section of Tempest Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tempest Therapeutics, Inc.
- Headquarters
- Brisbane, CA
- Address
- 2000 Sierra Point Parkway, Suite 400 94005
- Phone
- (415) 798-8589
- Website
- tempesttx.com
- Employees
- 4, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- TPST
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2012
- Shares outstanding
- 15M, May 8, 2026
- Public float
- $30.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-13 reverse, May 13, 2025; 1-for-13 reverse, Apr 9, 2025; 1-for-15 reverse, Jun 28, 2021; 1-for-50 reverse, Apr 1, 2019; 1-for-15 reverse, Dec 10, 2018
- SEC CIK
- 1544227
- CUSIP
- 87978U207
- ISIN
- US87978U2078
- LEI
- 529900QLMOA3D8VSCN33
- EIN
- 45-1472564
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Angel | CEO and President, Director | 5,068,552 |
| Stephen R. Brady | President and CEO, Director | 46,376 |
| Nicholas Maestas | Chief Financial Officer | – |
| Justin Trojanowski | Corporate Controller | 22,168 |
| Samuel Whiting | Chief Medical Officer | 9,573 |
| John D. Yee | Director | – |
| William Drake Richey | Director | 2,000 |
| Ronit Simantov | Director | – |
| Geoffrey Nichol | Director | – |
| Christine A. Pellizzari | Director | – |
| Michael Raab | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Mr.Brady | $1.87M | -$1.70M | $842.34K | $16 | – |
| FY2023 Mr.Brady | $7.01M | $4.38M | $2.35M | $83 | – |
| FY2022 Mr.Brady | $1.51M | $596.71K | $966.99K | $22 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had four employees, including four full-time employees and three holding Ph.D., MBA and/or M.S.”
Corporate history
Events identified from SEC filings